Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Move. Cheer. Dance. Do the wave. How to tap into the collective joy of 'we mode' - 2Novartis to build manufacturing hub in North Carolina, creating 700 jobs
- 3The most effective method to Boost Benefits in Gold Speculation: Master Techniques and Tips
- 4Astronomers detect rare 'free floating' exoplanet 10,000 light-years from Earth
- 5Every year, she thanks the trooper for the arrest that led to her sobriety
- Vote in favor of your Number one Sort of Cap
- Hanwha Ocean secures orders worth $866m for five vessels
- Dick Van Dyke shares his secrets to longevity as he turns 100
- Eight arrested in joint Scotland and Spain gang raids
- Interstellar comet 3I/ATLAS reveals weird wobbling jets in rare sun-facing tail
- Sydney Sweeney's American Eagle campaign and Kendrick Lamar's Super Bowl performance were among the 10 biggest pop-culture moments of 2025
- 5 Worldwide Road Food varieties You Should Attempt
- Emotional wellness Matters: My Fight with Tension
- The risk of falling space junk hitting airplanes is on the rise, experts warn
